Complement Therapeutics

📍 Munich, Germany👥 24 employees💰 Last funded Apr 2023
Biotechnology🌐 complementtx.com
Website LinkedIn
Complement Therapeutics GmbH (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade. Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions. The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Belgium
1
Frequently asked questions
Who invested in Complement Therapeutics?
Complement Therapeutics has 1 investors on record on gritt.io.
When did Complement Therapeutics last raise funding?
The most recent investment in Complement Therapeutics recorded on gritt.io was in April 2023.
What industry is Complement Therapeutics in?
Complement Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Complement Therapeutics based?
Complement Therapeutics is headquartered in Munich, Germany.